Market Intelligence, Clinical Progress, and High-Purity Reagents for Stromal and Solid Tumor Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LRRC15 drug discovery.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LRRC15 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View LRRC15 Products |
| Gene Delivery | LRRC15 Lentivirus Premade Particles Full-length ORF for stable cell line generation in CAF and tumor cells. |
View LRRC15 Products |
| Benchmark Ab | Anti-LRRC15 (Sequence of ABBV-085) Recombinant positive control for ADC development. |
View LRRC15 Products |
| Validator | LRRC15 siRNA Set For knockdown verification and specificity controls. |
View LRRC15 Products |
| Related Target: FAP | Fibroblast Activation Protein Complementary CAF marker for dual-stromal targeting. |
View FAP Products |
| Related Target: TGFB1 | TGF-β1 Upstream driver of LRRC15 expression in the tumor microenvironment. |
View TGFB1 Products |
| Related Target: PDGFRB | PDGF Receptor Beta Pericyte/CAF marker; alternative stromal compartment access. |
View PDGFRB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ADC Internalization & Stromal Penetration | High-purity ECD-Fc (>95%) with native glycosylation; suitable for pH-sensitive dye conjugation and internalization assays. |
| Cross-species Preclinical Evaluation | Human/Mouse/Cynomolgus LRRC15 ortholog proteins available with sequence-verified extracellular domain coverage. |
| Subfamily Off-target Screening (LRR Family) | LRRC8A, LRRC32, LRRC57 homolog panel proteins verified by mass spec for counter-screening. |
| Lack of Validated Positive Controls | Clinical Benchmark Antibodies (ABBV-085 sequence-matched biosimilars) included. |
| False Positives in CAF Screening | Validated siRNA included for specificity checks and target validation. |
| Cell Line Construction (CAF Models) | Lentivirus for stable expression in fibroblast lines; preserves native conformation for flow cytometry. |
Live LRRC15 R&D Tracker
Access the latest global pipeline status:
Global Clinical Landscape & Future Outlook
The race for LRRC15-targeted therapeutics represents a paradigm shift in solid tumor oncology, moving from direct tumor cell targeting to the modulation of the tumor microenvironment (TME). As a leucine-rich repeat-containing protein highly expressed on cancer-associated fibroblasts (CAFs) and select tumor epithelia, LRRC15 offers a unique stromal access strategy for antibody-drug conjugates (ADCs).
Current clinical momentum is dominated by AbbVie's ABBV-085, which has demonstrated preliminary efficacy in stroma-rich malignancies including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and sarcoma. The next wave of R&D is focusing on combination strategies with immune checkpoint inhibitors and the development of next-generation ADCs with optimized linker-payload technologies to enhance therapeutic window. Additionally, bispecific modalities and CAR-T therapies are emerging to overcome physical TME barriers and enhance immune cell infiltration.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | AbbVie (ABBV-085), Eli Lilly | PDAC, NSCLC, HNSCC, Sarcoma, Glioblastoma | Internalization & Stromal Penetration Assay (Need high-purity ECD-Fc) |
| Bispecific / TCE | Emerging Biotechs | Solid Tumors (Stroma-rich) | Heterodimer Validation (Need Cross-reactive Abs) |
| CAR-T / NK Cell Therapy | Academic / Emerging Biopharma | Stromal-rich Solid Tumors | Cell-based Cytotoxicity Assays (Need Lentivirus-stable target cell lines) |
Technical Specifications for Optimal Assay Performance
- Sequence Accuracy: LRRC15 ECD (Asp26-Ser538, UniProt Q8TF66) contains 15 LRR repeats and all predicted N-glycosylation sites (Asn154, Asn275, Asn405), ensuring authentic post-translational modifications for antibody binding.
- Native Conformation, No Tags: HEK293-expressed ECD-Fc maintains natural disulfide bonds and glycosylation, critical for conformation-dependent epitope recognition in internalization assays.
- Low Endotoxin: <1 EU/µg, meeting stringent ADC raw material requirements and avoiding false-positive endocytosis signals.